GC 3110A

Drug Profile

GC 3110A

Alternative Names: GC-3110A; GC-3110B; GCFlu Quadrivalent; Quadrivalent influenza virus vaccine - Green Cross Corporation; Seasonal influenza virus vaccine quadrivalent - Green Cross

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Green Cross
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza virus infections

Most Recent Events

  • 01 Oct 2016 Phase-III clinical trials in Influenza virus infections (Prevention, In the elderly) in South Korea (IM)
  • 28 Sep 2016 Green Cross plans a phase III trial for Influenza virus infections (In the elderly, Prevention) in South Korea (IM) (NCT02917304)
  • 27 Sep 2016 Green Cross Corporation plans a phase III trial for Influenza virus infections (Prevention) in Philippines (NCT02915809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top